Aubier M, Verster R, Regamey C, Geslin P, Vercken J B
Hôpital Bichat, Service de Pneumologie, Paris, France.
Clin Infect Dis. 1998 Jun;26(6):1312-20. doi: 10.1086/516366.
The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae. Success of treatment was determined by a combination of clinical assessment and chest radiography. Pneumococcal pneumonia was the confirmed diagnosis for 177 patients (54%). Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin, 89%; amoxicillin, 84%). Sparfloxacin was well-tolerated and produced fewer gastrointestinal effects than amoxicillin. In conclusion, sparfloxacin is a safe and effective alternative to high-dose amoxicillin for the treatment of suspected pneumococcal community-acquired pneumonia.
这项针对329名需要住院治疗的成年患者的随机、双盲、多中心研究的目的是，比较每日一次服用200毫克司帕沙星（第1天给予400毫克负荷剂量后）与每日三次口服1克阿莫西林治疗疑似肺炎链球菌引起的社区获得性肺炎的安全性和有效性。治疗成功与否由临床评估和胸部X光检查共同判定。177名患者（54%）确诊为肺炎球菌肺炎。在可评估患者中，两种药物在治疗结束时（司帕沙星，92%；阿莫西林，87%）和随访时（司帕沙星，89%；阿莫西林，84%）的总体成功率相当。司帕沙星耐受性良好，胃肠道不良反应比阿莫西林少。总之，司帕沙星是治疗疑似肺炎球菌社区获得性肺炎的一种安全有效的替代高剂量阿莫西林的药物。
